Patient's question:
After that, let's go for lymphatic drainage therapy. My result showed elevated D-dimer, with the reference value at 0.352. My first test result was 0.487, and after 13 days, the second test result was 0.522.Doctor's answer:
Clinical Significance D-dimer primarily reflects fibrinolytic function. Elevated or positive levels are seen in secondary fibrinolysis hyperactivity, such as hypercoagulable states, disseminated intravascular coagulation (DIC), kidney disease, organ transplant rejection, thrombolytic therapy, etc. As long as there is active thrombus formation and fibrinolysis in the body's vasculature, D-dimer levels will rise. Myocardial infarction, cerebral infarction, pulmonary embolism, venous thrombosis, surgery, tumors, DIC, infection, and tissue necrosis can all lead to elevated D-dimer levels. Particularly for the elderly and hospitalized patients, conditions like bacteremia are prone to causing coagulation abnormalities, resulting in elevated D-dimer levels.D-dimer testing has significant clinical relevance and applications. Measuring the main factors of the fibrinolytic system is crucial for diagnosing and treating fibrinolytic system diseases (e.g., DIC, various thromboses) and related diseases (e.g., tumors, pregnancy syndrome), as well as monitoring thrombolytic therapy. Elevated levels of fibrin degradation products indicate frequent fibrin degradation processes in the body. Therefore, fibrin D-dimer is a key indicator for deep vein thrombosis (DVT), pulmonary embolism (PE), and DIC.
Clinical Applications:
- Comparative studies on DVT diagnosis have shown that NycoCard D-Dimer and ELISA D-Dimer exhibit close consistency and sensitivity (near 100%) in negative judgments for DVT diagnosis compared to venography. In contrast, latex methods have a sensitivity of only 73% and consistency of 78%.
- NycoCard D-Dimer is an important tool for early DVT diagnosis and positive exclusion. It is simple, fast, and cost-effective.
□ Diagnosis of pulmonary embolism (PE) and arterial thrombosis
□ Diagnosis of disseminated intravascular coagulation (DIC)
□ Early testing of fibrinolytic mechanisms – prethrombotic risk assessment
□ High-risk pregnancy conditions and preeclampsia
□ Monitoring of thrombosis processes and thrombolytic therapy
□ Auxiliary diagnosis of tumors